Analyst Price Target is $8.00
▲ +572.27% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for BioVie in the last 3 months. The average price target is $8.00, with a high forecast of $11.00 and a low forecast of $5.00. The average price target represents a 572.27% upside from the last price of $1.19.
Current Consensus is
The current consensus among 2 polled investment analysts is to moderate buy stock in BioVie. This Moderate Buy consensus rating has held steady for over two years.
BioVie Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for the treatment of chronic debilitating conditions in the United States. Its products pipeline includes BIV201, which completed Phase IIa clinical trial for the treatment of ascites caused due to chronic liver cirrhosis; and NE3107, a potentially selective inhibitor of inflammatory extracellular single-regulated kinase, which is in Phase III clinical trial for the treatment of patients with mild to moderate Alzheimer's disease, as well as Phase 2 clinical trial for the treatment of Parkinson's disease. The company was formerly known as NanoAntibiotics, Inc. and changed its name to BioVie Inc. in July 2016. BioVie Inc. was incorporated in 2013 and is headquartered in Carson City, Nevada.